DRKS00009234已完成不适用
Biologica in patients with Crohn's disease in Germany - BioCrohn
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,550
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 80 Years（—）
- 性别
- All
入选标准
- •1. Crohn's disease patients (age at inclusion: 18-80 years ) with a new biologics therapy with Adalimumab, Infliximab, Certolizumab, Golimumab or Vedolizumab.
- •2. Crohn's disease patients (age at inclusion: 18-80 years ) with an early disease history (initial diagnosis < 3 years).
排除标准
- •Age under 18 years and over 80 years
研究者
相似试验
进行中（未招募）
1 期
Biological therapy in the prevention of Crohn`s disease recurrence after resection in ileocecal region.Prevention of Crohn`s disease recurrence after surgery in ileocecal region by postoperative application of infliximab (four infusions).MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's diseaseEUCTR2008-005688-32-CZniveristy Hospital Na Bulovce50
已完成
4 期
The influence of medication for Crohn's disease on serological response to the influenza vaccinatios diseaseCrohn's diseaseJPRN-UMIN000008043The Jikei University School of Medicine Division of Gastroenterology and Hepatology150
已完成
不适用
Therapeutic Effect of New Biologics in Crohn's DiseaseInflammatory Bowel DiseasesTreatment Side EffectsUlcerative ColitisCrohn DiseaseNCT04923100Sixth Affiliated Hospital, Sun Yat-sen University50
已完成
不适用
Gut microbiota in patients with Crohn's disease and their relativesCrohn's diseaseISRCTN19271131Barts and The London NHS Trust (UK)72
招募中
不适用
Validation of biomarkers for Crohn*s disease using peripheral blood cells of patientsulcerative colitiscrohn's diseaseNL-OMON48615Vrije Universiteit Medisch Centrum200